Abstract:
:Growth hormone deficiency (GHD) in the adult has now been fully recognised as a clinical entity characterised by abnormal body composition, osteopenia, impaired quality of life, cardiac dysfunction and an adverse lipid profile. While short-term studies of GH replacement have demonstrated irrefutably a favourable effect on all if not most features of GHD, data on long-term administration spanning more than 2 years are still scarce. Experience of GH replacement up to 5 to 10 years indicate that the beneficial effects on body composition, predominantly a decrease in body fat and an increase in lean mass, is maintained during treatment. Long-term GH therapy also increases muscle strength and exercise performance. All data, with one exception, are consistent with a significant increase in bone mass during prolonged GH therapy. The most distinct effect on bone was observed in the worst affected individuals and in males. Improvement in quality of life is documented shortly after initiation of GH replacement and is maintained during long-term studies. This may explain the reduction in days of sick leave seen during GH therapy. The beneficial effect on cardiovascular risk factors is sustained over a prolonged period of time, revealing a reduction in intima wall thickness, and an improvement in serum lipid levels and clotting parameters. The increase in lipoprotein(a) levels with GH therapy in some studies may be disturbing, but difficulties in measuring this parameter and inconsistencies between the different studies makes it difficult to estimate its real impact. No data are yet available to show that GH replacement will normalise or even improve mortality rate and fracture rate. Adverse events associated with GH replacement therapy are mainly secondary to fluid retention as a result of excess dose administration. This can be adequately prevented by monitoring GH replacement according to serum insulin-like growth factor (IGF)-I levels. From what is currently known, GH replacement does not increase the prevalence of diabetes mellitus, and does not induce new neoplasms or recurrence of the primary brain tumour; however, longer follow-up studies are needed to provide definitive answers. In conclusion, it appears not only that long-term GH replacement therapy in adults with GHD is a procedure that can be safely used, but that GH replacement should be considered as a possible life-long therapy in order to maintain its benefits.
journal_name
Drugsjournal_title
Drugsauthors
Verhelst J,Abs Rdoi
10.2165/00003495-200262160-00006subject
Has Abstractpub_date
2002-01-01 00:00:00pages
2399-412issue
16eissn
0012-6667issn
1179-1950pii
621606journal_volume
62pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::There is now good evidence that T cells play a central role in the inflammatory pathway that leads to the persistent synovitis that causes joint damage in rheumatoid arthritis (RA). T cells require two signals to become activated. The second step in the activation of T cells involves costimulatory pathways, the best d...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767010-00001
更新日期:2007-01-01 00:00:00
abstract::In recent years, there have been major advances in the management of rheumatoid arthritis (RA), leading to the development of tumour necrosis factor (TNF) antagonists. With these agents, it is possible to arrest joint damage and, by treating early in the disease course, to prevent joint damage. It is also now thought ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666140-00001
更新日期:2006-01-01 00:00:00
abstract::Migalastat (Galafold™)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations. Fabry disease is a rare disorder that results in a deficiency or absen...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-016-0607-y
更新日期:2016-07-01 00:00:00
abstract::Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01067-3
更新日期:2019-02-01 00:00:00
abstract::The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension. Verapamil IR was given in 3 divided doses (80 or 160mg 3 times daily) a...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-199200441-00002
更新日期:1992-01-01 00:00:00
abstract::The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA®] and for hyperphosphataemia in patients with chronic kidney disease (CKD) on dialysis or with end stage re...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01215-9
更新日期:2019-11-01 00:00:00
abstract::HIV causes chronic infection and is associated with persistent viral replication and a high viral mutation rate. It is an illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease. Monotherapy with antitubercular agents led to dramatic improvements in treatme...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199500491-00008
更新日期:1995-01-01 00:00:00
abstract:UNLABELLED:Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing intrastrand cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity and has demonstrated a lack of cross-resistance with other platinum compounds. In patients with metastatic colorectal cancer, intrav...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200060040-00005
更新日期:2000-10-01 00:00:00
abstract::Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161100-00004
更新日期:2001-01-01 00:00:00
abstract::The corticosteroid mometasone and the long-acting β(2)-selective adrenoreceptor agonist formoterol have been combined in a single pressurized metered-dose inhaler for use in patients aged ≥12 years with asthma. In a 26-week well designed trial in patients with persistent asthma uncontrolled on medium-dose inhaled cort...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11206920-000000000-00000
更新日期:2012-06-18 00:00:00
abstract::Trifluridine/tipiracil (Lonsurf(®)) is a novel, orally active, antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue, and tipiracil, a potent thymidine phosphorylase inhibitor. Trifluridine is incorporated into DNA via phosphorylation, ultimately inhibiting cell proliferation. Tipiracil...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0633-9
更新日期:2016-09-01 00:00:00
abstract::Utilising a modified fixed-dose, 4 x 3 factorial design, the antihypertensive effects of all combinations of 4 doses of pinacidil (0, 12.5, 25 and 37.5 mg bid) with 3 doses of hydrochlorothiazide (0, 12.5 and 25 mg bid) were studied in patients with supine diastolic blood pressure of 95 to 110mm Hg. The decreases in s...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198800367-00015
更新日期:1988-01-01 00:00:00
abstract::Hypertension affects 65 million people in the US, and is a major cause of morbidity and mortality, but less than one-third of patients with hypertension are treated to goal blood pressure. Multiple factors have been cited, and include suboptimal adherence to treatment and lifestyle modifications, limited access to hea...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666090-00006
更新日期:2006-01-01 00:00:00
abstract:UNLABELLED:The aminosalicylate balsalazide is a prodrug which is metabolised by bacterial azo reductases in the colon to release its therapeutically active moiety mesalazine [mesalamine (US) or 5-aminosalicylic acid] and an inert carrier molecule. The systemic absorption of balsalazide and its metabolites is not requir...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262110-00010
更新日期:2002-01-01 00:00:00
abstract::Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin an...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0666-0
更新日期:2017-01-01 00:00:00
abstract::Infliximab, the chimeric monoclonal antibody directed against tumour necrosis factor (TNF)-alpha, has profoundly changed therapy for Crohn's disease (CD). However, for ulcerative colitis (UC), before the publication of ACT 1 and ACT 2 (Active Ulcerative Colitis Trials 1 and 2), there were only a few open-label and con...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666160-00002
更新日期:2006-01-01 00:00:00
abstract:UNLABELLED:Dofetilide is a 'pure' class III antiarrhythmic agent which has demonstrated efficacy in the conversion of atrial fibrillation or flutter to sinus rhythm and the maintenance of sinus rhythm. By blocking the rapid component of the cardiac delayed rectifier potassium current (I(Kr)), dofetilide prolongs the ca...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958060-00007
更新日期:1999-12-01 00:00:00
abstract::The newest (third generation) fluoroquinolones are potentially useful agents in the management of community-acquired respiratory tract infections. This is mainly due to their increased activity against Streptococcuspneumoniae, a pathogen poorly susceptible to the second-generation compounds, and playing a major role i...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199957060-00002
更新日期:1999-06-01 00:00:00
abstract::25 patients have been included in a randomised trial aimed to compare prehospital and hospital administration of anisoylated plasminogen streptokinase activator complex (AP-SAC). Patients were first seen, at home, by a noncardiologist doctor working in a mobile-care unit and were then evaluated for entry into the stud...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700333-00042
更新日期:1987-01-01 00:00:00
abstract::Pain is associated with emotional and physical suffering that severely impacts quality of life. Many guidelines for the treatment of moderate to severe cancer pain indicate the use of opioids. For a small proportion of the global population, opioids are readily accessible, but are consequently also subject to risk of ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-020-01342-8
更新日期:2020-08-01 00:00:00
abstract::The simplest response to the question, what is the prevalence of hypertension in the United States today?, is given by a currently popular slogan: 23,000,000 Americans have hypertension. It is clear that the problem is large in scale, but this figure alone is an insufficient guide to many practical issues. The prevale...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-197600111-00006
更新日期:1976-01-01 00:00:00
abstract::Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clea...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01377-x
更新日期:2020-10-01 00:00:00
abstract::86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen ...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700333-00046
更新日期:1987-01-01 00:00:00
abstract::Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, thre...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11532200-000000000-00000
更新日期:2010-01-01 00:00:00
abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0565-4
更新日期:2016-04-01 00:00:00
abstract::Chronic spontaneous urticaria (CSU) is characterized by the presence of wheals, angioedema, or both for at least 6 weeks. It may persist for a long time-up to 50% of the patients have been reported to be symptomatic 5 years after the onset. Some patients can suffer more than one episode of CSU during their lifetime. C...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-020-01387-9
更新日期:2020-11-01 00:00:00
abstract::Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic car...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0469-8
更新日期:2015-09-01 00:00:00
abstract::Budesonide MMX(®) (Cortiment(®); Uceris(®)) is a novel once-daily oral formulation of budesonide using Multi Matrix (MMX(®)) colonic delivery technology to permit the release of budesonide at a controlled rate throughout the colon. It is available in the USA for the induction of remission in patients with active, mild...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0396-8
更新日期:2015-05-01 00:00:00
abstract::The endothelin family of peptides are extremely potent endogenous vasoconstrictor and pressor agents. Of the 3 isoforms, endothelin-1 is the major isoform produced by the vascular endothelium and is, therefore, likely to be of most importance for regulation of vascular function. Two endothelin receptor subtypes have s...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199651010-00003
更新日期:1996-01-01 00:00:00
abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01276-1
更新日期:2020-03-01 00:00:00